Savara Inc (SVRA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 17.60M USD | Liabilities, Current |
| Cash and equivalents | 41.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $17.60M | $41.80M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $15.54M | $38.79M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $20.40M | $33.18M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $16.76M | $16.28M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $13.63M | $17.44M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $11.90M | $19.56M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $14.72M | $15.13M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $12.79M | $21.43M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $11.29M | $23.86M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $9.81M | $16.79M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $10.60M | $26.59M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $8.96M | $27.69M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $5.88M | $22.75M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.92M | $33.98M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $5.87M | $52.10M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $5.16M | $119.84M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $3.71M | $95.15M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $16.32M | $79.23M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $14.66M | $34.01M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $10.66M | $44.70M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $5.63M | $40.65M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $7.21M | $55.98M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $8.17M | $22.88M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $7.64M | $35.22M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $6.45M | $47.12M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $7.73M | $34.52M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $10.88M | $49.80M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $8.29M | $17.79M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $9.05M | $16.83M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $8.92M | $25.67M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $7.25M | $24.30M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $11.22M | $24.95M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $7.52M | $23.60M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $5.39M | $22.12M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $6.01M | $22.12M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $6.08M | $19.81M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $8.14M | $61.13M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $6.59M | $7.77M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $4.87M | $8.54M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $20.89M | $20.52M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $25.36M | $24.49M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $22.67M | $23.52M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $23.17M | $23.05M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $13.52M | $32.21M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $10.80M | $21.21M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $9.18M | $27.93M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $8.44M | $35.81M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $7.51M | $25.98M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $5.75M | $26.37M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $6.17M | $29.85M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $4.83M | $25.68M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $3.98M | $30.23M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $3.33M | $44.97M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $3.16M | $21.41M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $2.57M | $22.50M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $2.66M | $26.09M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $2.49M | $29.96M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $1.95M | $35.05M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $2.47M | $43.57M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $3.12M | $32.77M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $2.36M | $41.96M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $46.55M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.80M | $27.98M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $29.33M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $31.16M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $8.67M | (m) | (m) | (m) | (m) |
| 1996-09-12 | (m) | (m) | $32.77M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |